Bristol-Myers Squibb has entered into a definitive agreement to acquire Flexus Biosciences, a privately held biotechnology company focused on novel anti-cancer therapeutics, for a potential total consideration of $1.25 billion, including $800 million upfront and development milestones. The transaction has been approved by both boards and is expected to close during 1Q15, subject to customary closing conditions.   BMS will gain full rights to Flexus’ lead preclinical small molecule, F001287, an I...